For patients with T2DM and Stage 2 or 3 CKD. Multicenter Study of the effects of Invokana on renal and cardiovascular outcomes in patients with Diabetes and Diabetic Nephropathy. Assessing the efficacy of Invokana – vs – placebo in reducing end-stage kidney disease. Total study duration is 5.5 years. To be eligible, must have a documented eGFR of >30 to <90 and a UACR of >300 to <5000 mg/g. Participants will be on maximum tolerated dose of ACE or ARB (can be added/adjusted during screening process). A1C inclusion is >6.5 to <10.5. DIABETES TESTING SUPPLIES AND STUDY DRUG PROVIDED AT NO COST. Most study participants receive stipend for each visit completed, in addition to safety assessments (labs, EKGs, Physician exams, etc).
© 2018 Hillcrest Clinics. All Rights Reserved. | Privacy Statement
If you have a concern regarding the quality of care you received during your treatment at any one of the Hillcrest Clinics, or simply want to discuss an experience you may have had, please call our dedicated Patient Relations phone number at (254) 202-9680 Monday through Friday 8:00am-5:00pm.

To register a complaint about any provider or clinic with the Texas Medical Board, please click on the following link: Texas Medical Board.

The Hillcrest Clinics Websites are wholly owned and operated by HFHC (Hillcrest Family Health Centers). The websites, email your doctor, and the Hillcrest Clinics Patient Portal are for NON-EMERGENCY USE ONLY. Please allow up to 48 hours for a reply when using “Email Your Doctor” or the “Hillcrest Clinics Patient Portal”.
If you are experiencing an emergency, please call 9-1-1 or go to your nearest emergency room.